PHASE 1 FIRST IN HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GRC54276, A NOVEL HPK1 THRONINE-KINASE INHIBITOR, IN ADVANCED SOLID TUMOURS AND LYMPHOMAS.
EHA Library, Harsha Doddihal,
387360
CLINICAL FEATURES, TREATMENT PATTERNS, AND OUTCOMES AMONG 120 PATIENTS WITH MALT LYMPHOMA IN LATIN AMERICA: A STUDY FROM THE GRUPO DE ESTUDIO LATINOAMERICANO DE LINFOPROLIFERATIVOS (GELL)
EHA Library, Alana von Glasenapp,
387366
TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
EHA Library, Seok-Goo Cho,
387381
ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
EHA Library, Kim Linton,
387398
CHIDAMIDE WITH AZACITIDINE AND CHOP TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA:INTERIM ANALYSIS OF A PROSPECTIVE,SINGLE CENTER,SINGLE-ARM, PHASE 2 TRIAL
EHA Library, Chunyan Xiao,
387411
ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
EHA Library, Jason Westin,
387419